2023
Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes
Moura F, Berg D, Bellavia A, Dwyer J, Mosenzon O, Scirica B, Wiviott S, Bhatt D, Raz I, Feinberg M, Braunwald E, Morrow D, Sabatine M. Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. Diabetes Care 2023, 46: 1807-1815. PMID: 37556796, PMCID: PMC10516252, DOI: 10.2337/dc23-0492.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2Kidney disease progressionPredictors of kidney disease progressionAbsolute risk reductionDisease progressionValidation cohortType 2 diabetesSodium-glucose cotransporter 2 inhibitionUrine albumin-to-creatinine ratioAlbumin-to-creatinine ratioEfficacy of dapagliflozinMedian follow-upRisk categoriesMultivariate Cox regressionRelative risk reductionHigh-risk groupAtherosclerotic cardiovascular diseaseSystolic blood pressureRisk reductionMagnitude of benefitDapagliflozin EffectT2D durationCotransporter 2SGLT2 inhibitionStratify riskAssessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus
Berg D, Moura F, Bellavia A, Scirica B, Wiviott S, Bhatt D, Raz I, Bohula E, Giugliano R, Park J, Feinberg M, Braunwald E, Morrow D, Sabatine M. Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus. Journal Of The American College Of Cardiology 2023, 81: 2391-2402. PMID: 37344040, PMCID: PMC11466046, DOI: 10.1016/j.jacc.2023.04.031.Peer-Reviewed Original ResearchConceptsType 2 diabetes mellitusSecondary preventionIschemic strokePredictor of MIValidation cohortClinical decision-makingRates of MIMyocardial infarctionAtherothrombotic eventsRisk quintileRisk of atherothrombotic eventsRisk modelSelection of pharmacotherapyRisk scoreAssessed clinical variablesMultivariate Cox regressionClinical trial cohortPooled cohortCandidate variablesCox regressionIS ratesDECLARE-TIMIAbsolute reductionTrial cohortCohort
2019
Excess weight mediates changes in HDL pool that reduce cholesterol efflux capacity and increase antioxidant activity
de Lima-Junior J, Virginio V, Moura F, Bertolami A, Bertolami M, Coelho-Filho O, Zanotti I, Nadruz W, de Faria E, de Carvalho L, Sposito A. Excess weight mediates changes in HDL pool that reduce cholesterol efflux capacity and increase antioxidant activity. Nutrition Metabolism And Cardiovascular Diseases 2019, 30: 254-264. PMID: 31753789, DOI: 10.1016/j.numecd.2019.09.017.Peer-Reviewed Original ResearchConceptsCarotid intima-media thicknessBody mass indexCholesterol efflux capacityReduced cholesterol efflux capacityNon-diabetic individualsNon-obeseHDL-CIncreased values of BMIAtherosclerotic burdenEfflux capacityValues of body mass indexElevation of body mass indexProtective function of HDLIncreased BMIObesity-related declineInhibition of platelet aggregationHigh-density lipoprotein (HDLIncreased atherosclerotic burdenAssociated with carotid intima-media thicknessIncreased HDL-CDecreased HDL concentrationIntima-media thicknessFunction of HDLLipoprotein (HDLPlatelet aggregation inhibition
2012
Atherosclerotic disease in octogenarians: A challenge for science and clinical practice
Freitas W, Carvalho L, Moura F, Sposito A. Atherosclerotic disease in octogenarians: A challenge for science and clinical practice. Atherosclerosis 2012, 225: 281-289. PMID: 22858284, DOI: 10.1016/j.atherosclerosis.2012.06.070.Peer-Reviewed Original Research